The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...